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Abstract
Background: Ovarian granulosa cells are the predominant source of estradiol and progesterone
biosynthesis in vivo. Rosiglitazone, a synthetic agonist of the peroxisome proliferator-activated
receptor gamma (PPAR gamma), is applied as the treatment of insulin resistance including women
with PCOS. The aim of the study was to investigate the direct effects of rosiglitazone on
steroidogenesis and proinflammatory factor production in human granulosa-lutein cells (GLCs).
Methods: Primary human GLCs were separated during in vitro fertilization and cultured in the
presence of rosiglitazone, GW9662 (an antagonist of PPAR gamma) and hCG. The mRNA
expression of key steroidogenic factors including 3beta- hydroxysteriod dehydrogenase (3beta-
HSD), cytochrome P-450 scc (CYP11A1), cytochrome P-450 aromatase (CYP19A1), and
steroidogenic acute regulatory protein (StAR) were detected by quantitative real-time PCR.
Estradiol and progesterone levels in GLCs cultures were measured by chemiluminescence
immunoassay, and the proinflammtory factors (TNFalpha and IL-6) in conditioned culture media
were measured by ELISA.
Results: PPAR gamma mRNA levels increased up to 3.24 fold by rosiglitazone at the concentration
of 30 microM compared to control (P < 0.05). hCG alone or hCG with rosiglitazone had no
significant effects on PPAR gamma mRNA levels. The CYP19A1 mRNA level at exposure to
rosiglitazone alone showed a drop, but was not significantly reduced comparing to control. The
expression levels of enzymes 3beta-HSD and CYP11A1 in all treatments did not alter significantly.
The StAR mRNA expression at exposure to rosiglitazone was significantly increased comparing to
control (P < 0.05). The media concentrations of E2 and progesterone by rosiglitazone treatment
showed a declining trend comparing to control or cotreatment with hCG, which did not reach
significance. Most importantly, treatment with rosiglitazone decreased TNFalpha secretion in a
statistically significant manner compared with control (P < 0.05). The concentration of IL-6
following rosiglitazone exposure did not significantly decrease comparing to control.
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Conclusion: In cultured GLCs, rosiglitazone stimulated StAR expression, but did not significantly
affect steroidogenic enzymes, as well as E2 and progesterone production. Moreover, rosiglitazone
significantly decreased the production of TNFalpha in human GLCs, suggesting that PPAR gamma
may play a role in the regulation of GLCs functions through inhibiting proinflammatory factors.
Background
Peroxisome proliferator-activated receptor γ (PPARγ), a
well-studied member of the nuclear receptor superfamily,
has been implicated in numerous biological processes,
including adipocyte differentiation, regulation of lipid
and glucose homeostasis, and control of inflammatory
responses [1-3]. PPARγ represents important targets for
obesity, obesity-induced inflammation, and metabolic
syndrome in general. PPARγ agonist, thiazolidinedione
(TZD, including troglitazone, rosiglitazone and pigolita-
zone), is currently used to treat type diabetes (NIDDM)
and also to attenuate the secondary clinical symptoms fre-
quently associated with insulin resistance including poly-
cystic ovary syndrome (PCOS) [1-4]. Given that
troglitazone has been withdrawn from the market because
of hepatotoxicity and one of the important current availa-
ble PPAR agonists, rosiglitazone, has a binding affinity for
PPARγ 100-fold greater than that of troglitazone [3].
In the ovary, PPARγ is expressed most strongly in granu-
losa cells, and less strongly in theca cells and corpora lutea
[5]. The PPARγ is involved in varied processes such as ster-
oidogenesis, angiogenesis, tissue remodeling, cell cycle,
apoptosis, and lipid metabolism, which are critical for
normal ovarian function. Recently, using the mouse
mutant model, granulosa cell-specific deletion of PPARγ
resulted in marked impairment of ovulation owing to
defective follicular rupture and thereby discovered a criti-
cal ovarian function of this factor [5]. Rosiglitazone can
directly influence ovarian function and ultimately exert
positive effects on oocyte developmental competence in
mice [6]. Improved blastocyst quality in obese female
mice treated with rosiglitazone before mating indicated
that PPARγ was a key target for metabolic regulation of
ovarian function and oocyte quality [7].
In recent reports, administration of TZD to women with
PCOS resulted in a marked attenuation of hyperinsuline-
mia that was associated with improvements in insulin
secretion, ovarian androgen biosynthesis, and enhanced
fibrinolytic system capacity [1,3]. Although it is thought
that the inhibitory effects of rosiglitazone on ovarian
androgen production are a result of the reduction of circu-
lating insulin levels induced by rosiglitazone, in several in
vitro and in vivo studies in animal and human ovarian
cells, PPARγ agonists have been reported to directly
inhibit or increase activity of ovarian steroidogenic
enzymes, progesterone and estradiol (E2) production [8-
12]. To clarify the underlying mechanisms, experiments
with isolated granulosa cells culture derived from normal
women without endocrinological diseases are necessary.
Granulose-lutein cells (GLCs) isolated from follicular
fluid in in vitro fertilization- embryo transfer (IVF-ET) pro-
vides us a good source of experiment material.
PPARγ ligands including rosiglitazone also inhibit the
activation of inflammatory genes expression and can neg-
atively interfere with pro-inflammatory transcription fac-
tor signaling pathways in vascular and inflammatory cells
[13]. PPARγ was demonstrated to control a unique net-
work of downstream genes, including those encoding for
interleukin-6 (IL-6) and tumor necrosis factor-α (TNFα)
[13-15]. Because these cytokines have indispensable
effects in ovulation and luteinization [16,17], it is impor-
tant to understand the regulation of them by PPARγ in the
preovulatory granulosa cells, which may be of considera-
ble clinical significance during long-term therapy.
The objectives of this study were to determine the effects
of PPARγ agonist rosiglitazone on steroidogenesis and
proinflammtory factors production (TNFα and IL-6) in
cultured GLCs from infertile women due to tubal block-
age.
Methods
Subjects
This study was approved by the Institutional Ethics Com-
mittee of Shanghai Institute of Planned Parenthood
Research. All participants provided their informed con-
sent before inclusion in this study. A total of 20 infertile
women with tubal blockage undergoing controlled ovar-
ian hyperstimulation (COH) for in vitro fertilization-
embryo transfer were enrolled into the study. All of the
women had regular menstrual cycles and no evidence of
PCOS or other endocrinopathies.
Ovarian stimulation protocols were carried out following
our clinical routine described previously [18]. Briefly,
Patients in COH cycles received a long stimulation proto-
col with GnRH agonist and recombinant FSH treatment.
The GnRH-a (1.5 mg) was commenced on cycle day 21 of
the preceding luteal phase. The starting gonadotropin
dose was 150 IU/day, with the dose being adjusted in an
individual fashion after 6 days of ovarian stimulation. Ten
thousand units of hCG were given IM when the leading
follicle reached 18 mm and at least three follicles wereReproductive Biology and Endocrinology 2009, 7:147 http://www.rbej.com/content/7/1/147
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>15 mm in diameter. Transvaginal ultrasound-guided
oocyte retrieval was scheduled 33-36 hours after the hCG
injection.
Follicle fluid collection and GLCs culture
After oocyte retrieval, the follicular-aspirates containing
GLCs from 3-4 patients were pooled for GLCs culture. Fol-
licular aspirates were transported on ice to the laboratory
and centrifuged at 1000 rpm for 5 min. The pellet was
resuspended in PBS (Sigma Chemical Co., St. Louis, MO).
The GLCs were separated from the blood cells and cellular
debris using 50% percoll gradient centrifugation (Sigma)
for 20 minutes. After centrifugation, the interphase cells
were collected, washed with PBS by centrifugation for 5
minutes, and incubated with 0.1 mg/mL hyaluronidase
(Sigma) for 5-10 minutes in DMEM/F12. The dispersed
GLCs were centrifugated, washed and suspended in
DMEM/F12 containing 10% FBS, 100 U/ml penicillin, 0.1
mg/ml streptomycin. The GLCs were seeded in a flask.
Approximately 1 × 106 to 10 × 106 cells were obtained
from each patient. Cellular viability was assessed by 0.4%
Trypan blue exclusion test and ranged at 70-90%.
After 48 hours, the cells were washed to remove remaining
red blood cells which did not adhere to the plastic surface.
The cells were then incubated for 24-72 hours at 37°C in
DMEM/F12 containing 10% FBS in a humidified atmos-
phere with 5% CO2 in air with following treatments: (1)
basic media with 0.01% dimethylsulfoxide (DMSO); (2)
different dose of rosiglitazone (7.5 μM, 15 μM, 30 μM, 60
μM) and rosiglitazone 30 μM at different time (24 h, 48 h
and 72 h); (3) PPARγ antagonist GW9662 at the concen-
tration of 1 μM; (4) rosiglitazone at the concentration of
30 μM and GW9662 at the concentration of 1 μM; (5)
hCG at the concentration of 1 IU/mL; (6) rosiglitazone at
the concentration of 30 μM and hCG at the concentration
of 1 IU/mL. At the same time, 0.1 μM androstenedione
was added to the cultures as substrate for estrogen produc-
tion. Finally, the conditioned culture media were col-
lected for ELISA and chemiluminent assay. The cultured
GLCs were then removed from the dishes by a 5-minute
treatment at 37°C with 0.25% trypsin. The cells were col-
lected by centrifugation and stored at -80°C. All the treat-
ments were repeated 6 times.
RNA extraction, RT reaction and real-time PCR
Total RNA was extracted from GLCs using TRIzol (Invitro-
gen, Karlsruhe, Germany). Two micrograms of total RNA
were reverse transcribed into cDNA. Twenty microliters of
RT reaction mixture were used for RT -PCR. Forty nano-
grams of RNA, 2 μl of RT buffer, 10 IU of RNase Inhibitor,
2 μl of oligo (dT) (10 μM), 2 μl of dNTP-mix (2.5 mM)
and diethylpyrocarbonate (DEPC)-treated water up to 10
μl were mixed and incubated at 70°C for 5 min and then
immediately placed on ice. Next, 50 IU of Superscript II
Reverse Transcriptase was added. cDNA synthesis was car-
ried out at 37°C for 60 min. The reaction was stopped by
incubating at 72°C for 10 min. The samples were then
stored at -20°C until real-time PCR was performed.
Real-time PCRs were performed using Biorad Chromo4
real-time PCR detector (Bio-rad Co, CA, USA). The reac-
tion mixture consisted of 200 nM of each primer for tar-
geted genes, 12.5 μl SYB green PCR master mix and 9.5 μl
of the DEPC water, corresponding to a 0.5 ng mRNA in a
total reaction volume of 25 μl. The cDNA was denatured
at 95°C for 1 min. The template was then amplified over
36 cycles of 15 s of melting at 95°C, 15 s at 60°C for
annealing and 45 s at 70°C for extension. The threshold
cycle (Ct) values were normalized to β-actin levels. Rela-
tive mRNA levels were calculated using the 2-ΔΔCt method.
Primer sequences and the size of the expected PCR prod-
ucts for PPARγ and key steroidogenesis factors including
3β-hydroxysteriod dehydrogenase (3β-HSD), cytochrome
P-450 scc (CYP11A1), cytochrome P-450 aromatase
(CYP19A1), and steroidogenic acute regulatory protein
(StAR), as well as the endogenous control gene β-actin are
presented in Table 1. The specificity of the primers used in
the study was confirmed by agarose gel electrophoresis
and sequence analysis on the reaction products.
Hormone measurements
Concentrations of E2 and progesterone in the culture fluid
were determined by chemiluminescence immunoassay
using commercial kits obtained from Roche Diagnostics
GmbH (Mannheim, Germany). The supernatant was
diluted with the Assay Diluent (Roche Diagnostics
GmbH) by 50-200 folds when the sample generated value
greater than the highest standard. Practical detection lim-
its, within- and between assay coefficients of variation
Table 1: Primer pairs used for PCR amplification
Gene Genebank access no. Fragment length (bp) Forward primer sequence Reverse primer sequence
PPARγ NM_005037.5 161 GAGCCCAAGTTTGAGTTTGC CTGTGAGGACTCAGGGTGGT
3β-HSD NM_000198.2 196 GCCTGTTGGTGGAAGAGAAG ATGATACAGGCGGTGTGGAT
CYP11A1 NM_000781.2 200 GGAAATTACTCGGGGGACAT AACAGACGGAACAGGTCTGG
StAR NM_000349.2 157 TACGTGGCTACTCAGCATCG ACAGCAGGCTGGTCTTCAAC
CYP19A1 NM_031226.2 242 CAGAGGCCAAGAGTTTGAGG ACACTAGCAGGTGGGTTTGG
β-actin NM_001101.3 271 CTACAATGAGCTGCGTGTGGC CAGGTCCAGACGCAGGATGGCReproductive Biology and Endocrinology 2009, 7:147 http://www.rbej.com/content/7/1/147
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were 18.4 pmol/l, 5.4% and 10.5%, respectively, for E2
and 0.095 nmol/l, 6.2% and 9.5%, respectively, for pro-
gesterone.
Measurement of TNF  and IL-6
TNFα and IL-6 concentration in culture media were deter-
mined using human ELISA kit (R&D systems, Minneapo-
lis, MN). The lower limits of detectability of TNFα and IL-
6 were 12 pg/ml and 10 pg/ml, respectively. All measure-
ments were carried out in duplicate. The intra- and inte-
rassay coefficients of variation for TNFα were 8.5% and
10.3%. The intra- and interassay coefficients of variation
for IL-6 were less than 7.6% and 10%, respectively.
Statistical analysis
SPSS 11.5 was used for the data analysis. A one-way
ANOVA was used to estimate the statistical difference
between the treatment groups. Turkey test was used for
variables with normal distribution and the Dunnett's T3
test was used for variables with skewed distribution. A
value of P < 0.05 was considered significant.
Results
Effects of rosiglitazone, GW9662 and hCG on PPAR  
expression
The effect of rosiglitazone in different doses and time
course on PPARγ expression in the GLCs is shown in Fig-
ure 1. PPARγ expression was stimulated by rosiglitazone
which reached a peak point at the dose of 30 μM (3.24
fold compared to a DMSO control, P < 0.05). The mRNA
expression of PPARγ was increased by rosiglitazone and
no difference was found among three time points (24 h,
48 h and 72 h). In the subsequent experiments, the dura-
tion of incubation was standardized to 72 h and the dose
Effects of rosiglitazone on PPARγ mRNA level in cultured GLCs Figure 1
Effects of rosiglitazone on PPARγ mRNA level in cultured GLCs. A. Relative expression of PPARγ after rosiglitazone 
(Rosi) treatment for 72 h in different doses. B. Time course of rosiglitazone on PPARγ mRNA level in cultured GLCs. C. Rela-
tive expression of PPARγ in cultured GLCs in response to rosiglitazone treatment for 72 h in the presence or absence of 
GW9662 and hCG. Results are expressed in ratio to β-actin, and presented as means ± SD of six independent experiments. 
Statistical significances compared to the DMSO control are shown with one asterisk (P < 0.05).Reproductive Biology and Endocrinology 2009, 7:147 http://www.rbej.com/content/7/1/147
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of rosiglitazone was 30 μM. When the cells were cotreated
with GW9662, it partly reversed the effects of rosiglita-
zone in terms of PPARγ production but no significant dif-
ference was achieved. In addition, no significant effects on
PPARγ production were shown after treatment with hCG
alone or hCG together with rosiglitazone.
Effects of rosiglitazone, GW9662 and hCG on 
steroidogenesis
The mRNAs expression of key steroidogenic factors
(CYP19A1, CYP11A1, 3β-HSD and StAR) in GLCs are
shown in Figure 2. The CYP19A1 mRNA expression fol-
lowing exposure to rosiglitazone showed a reducing trend
but no significance was achieved comparing to the DMSO
control. Cotreatment with hCG did not change CYP19A1
mRNA levels. The expression of 3β-HSD and CYP11A1
involved in progesterone synthesis did not alter at expo-
sure to rosiglitazone, comparing to control or cotreatment
with GW9662 and hCG. On the other hand, the StAR
mRNA expression at exposure to rosiglitazone was dra-
matically increased compared with the DMSO control (P
< 0.05), and this was attenuated by hCG and GW9662.
The levels of E2 and progesterone from the supernatant of
GLCs cultures in the presence or absence of rosiglitazone,
GW9662 and hCG for 72 hours were also examined (Fig-
ure 3). Rosiglitazone alone did not decrease E2 and pro-
gesterone levels compared with the control. In the
presence of GW9662, E2 and progesterone levels in the
exposure to rosiglitazone also showed no change com-
pared with the control group (P > 0.05). Likewise, co-
treatment with hCG demonstrated a decreasing trend on
E2 and progesterone production, but did not achieve a sig-
nificant difference.
Effects of rosiglitazone, GW9662 and hCG on TNF  and IL-
6 secretion
Secretion of TNFα and IL-6 by cultured GLCs in different
treatments is shown in Figure 4. Treatment with rosiglita-
zone alone or with the presence of GW9662 decreased
TNFα secretion in a statistically significant manner com-
pared with a DMSO control (P < 0.05). No significant dif-
ference was observed with hCG exposure alone, or
together with rosiglitazone.
Regulation of steroidogenic factors by rosiglitazone, GW9662 and hCG in cultured GLCs Figure 2
Regulation of steroidogenic factors by rosiglitazone, GW9662 and hCG in cultured GLCs. The granulosa cells 
were treated with rosiglitazone alone, or together with GW9662 and hCG for 72 h. The relative expressions of CYP19A1 (A), 
3β-HSD (B), CYP11A1 (C), StAR (D) were measured by real-time RT-PCR. Results in folds of β-actin are expressed as means 
± SD of six independent experiments. Statistical significances compared to the DMSO control are shown with one asterisk (P 
< 0.05).Reproductive Biology and Endocrinology 2009, 7:147 http://www.rbej.com/content/7/1/147
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Rosiglitazone decreased IL-6 secretion, whereas did not
reach statistical significance. With the presence of
GW9662 or hCG, similarly, IL-6 did not change signifi-
cantly.
Discussion
In order to explore the possible direct effects of rosiglita-
zone on human GLCs, we have investigated the produc-
tion of steroid hormones and proinflammatory factors in
GLCs in in vitro culture exposure to PPARγ agonist and
antagonist. The results indicated that rosiglitazone signif-
icantly stimulated StAR mRNA expression, but did not
affect steroidogenic enzymes, neither E2 nor progesterone
production. More interestingly, rosiglitazone significantly
decreased TNFα levels in GLCs. Thus, PPARγ may play a
role in the regulation of GLCs functions through inhibit-
ing proinflammatory factors.
Despite that in vitro studies may not necessarily reflect
normal physiology in vivo, in vitro experiments may be
vital to increase our knowledge of the way in which rosigl-
itazone influences the function of GLCs. Our data expli-
cated that PPARγ expression was stimulated by
rosiglitazone and the greatest response was observed at
the concentration of 30 μM. The time course was found
no difference among the incubation time 24-72 h. There-
fore rosiglitazone 30 μM at 72 h incubation was used for
our further experiments and was also approximately com-
parable to the reports [8,19]. The widely-used selective
PPAR antagonist, GW9662, partially reversed the effects of
rosiglitazone in terms of PPARγ production, though not
significantly. It has been reported that GW9662 could reg-
ulate cell growth at high dosages independent of PPARγ
[20,21] and this may be the reason for not completely
reversing the effect of rosiglitazone.
In nonreproductive tissues, PPARγ has been shown to
have a variety of actions within resident macrophage
immune cells such as regulating cytokine mRNA expres-
sion to modulate overall inflammatory response [15].
TZD activation of PPARγ affect monocyte/macrophage
function by downregulating transcription of proinflam-
matory genes such as inducible nitric oxidase synthase
(NOS2), IL-1β, IL-6, IL-12 and TNFα [14,15,22,23]. The
present study showed for the first time that TNFα was sig-
nificantly suppressed by rosiglitazone in cultured GLCs.
Whereas IL-6 secretion after rosiglitazone treatment
appeared to decrease, although this did not achieve signif-
icance. TNFα is a multifunctional hormone-like polypep-
tide and modulates many genes involved in
inflammation, infection, and malignancy [17]. Although
macrophages are a main source of TNFα, GLCs and cor-
pora lutea have been reported to contain TNFα [24].
TNFα is well known in regulating steroidogenesis, ovula-
tion and luteinization in numerous species including
rodents and humans [25-27]. PPARγ played a major role
in ovulation because conditional loss of the PPARγ gene
in GLCs did not affect ovarian follicular development but
prevent follicular rupture [5]. It was supposed that PPARγ
may be involved in ovulation and luteinization by inhib-
iting the secretion of TNFα in GLCs in the present study.
The detail mechanism remains unclear and needs further
study.
Steroidogenic acute regulatory protein (StAR) plays an
essential role in cholesterol transfer from the outer to the
inner mitochondrial membrane, thus providing the sub-
strate for steroid hormone biosynthesis [9-11]. Choles-
terol is then converted to pregnenolone by the CY11A1
enzyme, initiating steroid biosynthesis. In the present
study, rosiglitazone stimulated the StAR mRNA up to 2.6
fold, the results suggested that activation of steroid hor-
mone synthesis by rosiglitazone may be mediated via acti-
vation of StAR. In the previous report, the insulin or TZDs
up-regulated PPARγ, insulin receptor, insulin receptor
substrate-1 and StAR protein expression, so it were pre-
sumed that PPARγ, StAR protein and insulin receptor con-
stituted a novel system of ovarian regulation [19].
The steroid hormone production is a multi-step process,
requiring action of multiple enzymes. In the present
study, the changes of key steroidogenic enzymes
(CYP19A1, CYP11A1 and 3β-HSD) induced by rosiglita-
zone were not obvious in the GLCs. Moreover, the non-
significant results for rosiglitazone affecting concentra-
Effects of rosiglitazone, GW9662 and hCG on steroid hor- mone production in cultured GLCs Figure 3
Effects of rosiglitazone, GW9662 and hCG on steroid 
hormone production in cultured GLCs. Concentrations 
of E2 (A) and progesterone (B) in the culture fluid of GLCs 
treated with or without rosiglitazone, GW9662 and hCG for 
72 h. Values are means ± SD of six independent experiments.Reproductive Biology and Endocrinology 2009, 7:147 http://www.rbej.com/content/7/1/147
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tions of E2 and progesterone were coincident with the
aboved changes of steroidogenic enzymes. So in the
present study, although PPARγ stimulated StAR mRNA
expression, the activation of PPARγ did not play a major
role in the regulation of steriod hormone production in
the cultured GLCs.
In the present study, the effects of rosiglitazone on ster-
oidogenesis were different from some previous reports.
Rosiglitazone directly stimulated progesterone and
IGFBP-1 production, while inhibited E2 and testosterone
production using a culture system of mixed ovarian cells
[8]. Troglitazone suppressed progesterone production
specially by inhibiting the activity of 3β-HSD in porcine
granulosa cells [9,11]. In our study, the GLCs isolated
from follicular fluid in IVF-ET was in the final stage of dif-
ferentiation, the responses to rosiglitazone were possibly
different from the cells obtained from oophorectomy
specimens in human and porcine.
In contrast with the previous report that hCG stimulation
induced a transcriptional burst of genes involved in pro-
gesterone synthesis (3β-HSD, CYP11A1 and StAR) using
luteinized granulosa cells [28], no significant changes
were found regarding key steroidogenic enzymes and
proinflammatory factors when adding hCG to the GLCs.
The fact could not be ignored that the GLCs obtained
from IVF patients at the time of oocyte retrieval have
received superphysiological doses of gonadotrophins
before they were put into culture. The GLCs may have
gonadotrophin desensitization due to their over exposi-
tion to FSH and LH treatment in vivo so they can not
obtain marked response by adding another gonado-
trophin stimulant. Similar results were reported in the
previous studies [29-31].
In order to determine the action of PPARγ on steroidogen-
esis in GLCs, more convincing data could be obtained by
knocking down of PPARγ expression using human PPARγ
siRNA in cultured GLCs. Given that primary GLCs are dif-
ficult to transfer using siRNA, the immortalized granulosa
cell lines will be good candidate for studying the regula-
tion mechanism of PPARγ.
Conclusion
In summary, although rosiglitazone stimulated StAR
expression in human GLCs, the results demonstrated that
rosiglitazone did not significantly inhibit E2 and proges-
terone productions in cultured GLCs, Moreover, rosiglita-
zone significantly decreased the production of TNFα in
human GLCs, suggesting that PPARγ may play a role in the
regulation of GLCs functions through inhibiting proin-
flammatory factors. Further studies need to investigate the
molecular regulating mechanism of PPARγ on the GLCs.
Careful attention also needs to be paid to the possibility
that long-term treatment with rosiglitazone in patients
with NIDDM and PCOS might also cause unexpected side
effects, such as ovarian dysfunction.
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